Research targets the development of face masks
and other products that inactivate viruses
SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the
“Company”), an original equipment manufacturer of silicon nitride
ceramic for medical and non-medical applications, announced new
studies confirming that its material inactivates SARS-CoV-2, the
causative agent of the COVID-19 pandemic, as well as the Influenza
A virus that is responsible for the common cold.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20200902005308/en/
Illustration of SARS-CoV-2 showing spikes
on the outer surface of the virus. (Graphic: Business Wire)
Previous findings had shown that SINTX’s silicon nitride can
inactivate SARS-CoV-2, as well as other single-strand RNA (ssRNA)
viruses such as Influenza A, Feline calicivirus, and Enterovirus.
Those findings were first reported in June 2020 on BioRxiv, a
pre-print server for COVID-19 research ahead of peer review. Data
related to the other ssRNA viruses are under peer review for
publication.
The latest SARS-CoV-2 testing was done at the National Center
for Biodefense and Infectious Diseases, George Mason University,
Virginia (GMU). The study was designed to (1) reproduce the earlier
findings using an independent institution and study protocol, and
(2) show a time-and-dose-dependent antiviral effect of silicon
nitride, and (3) establish a U.S.-based testing facility for future
testing of commercial products, such as fabrics containing silicon
nitride.
The GMU data confirm that silicon nitride strongly inhibits
SARS-CoV-2, after just one minute of exposure. The anti-viral
effect increases with higher doses and longer duration of exposure
to silicon nitride. Importantly, silicon nitride is non-toxic to
mammalian cells, a finding that is consistent with the successful
clinical outcomes of SINTX’s spinal implants made of the same
material as was tested at GMU.
Separate testing at another contract research facility, ImQuest
BioSciences, Frederick, Maryland, showed that SINTX’s silicon
nitride strongly inactivates the Influenza A virus as well.
Selected data from that testing is shown in the graph above.
“The ability of silicon nitride to effectively terminate the
SARS-CoV-2 and Influenza A viruses is of importance, as the world
braces for the flu season, with SARS-CoV-2 still around,” said Dr.
Sonny Bal, President, and CEO of SINTX Technologies. “We are moving
at full speed to incorporate silicon nitride into consumer masks
that will catch-and-kill these respiratory pathogens. Beyond face
masks, the antipathogenic advantages of silicon nitride will
benefit schools, nursing homes, hospitals, casinos, cruise ships,
day-care centers, commercial travel, and many other markets. Our
R&D will advance the science, while external partners develop
commercial products.”
“We are excited to get the results from this study as they
solidify what we already know about SINTX and to continue efforts
around bringing a mask to market,” said Bruce Lorange, CEO of
O2TODAY, the company with whom SINTX has entered an agreement to
develop face masks. “The latest data from SINTX is a solid
confirmation of silicon nitride’s promise toward combatting the
spread of COVID-19 and the flu, both of which are global
worries.”
The COVID 19-driven demand for antipathogenic materials goes
beyond face masks. As such, SINTX is identifying new revenue
opportunities in industries such as automotive, aerospace,
biomedicine, and others. The company is in discussions with
prospective partners interested in developing a variety of
products, such as automotive parts, cell phone cases, air filters,
and medical PPE. SINTX looks forward to sharing additional
developments in the coming months.
About SINTX Technologies, Inc.
SINTX Technologies is an OEM ceramics company that develops and
commercializes silicon nitride for medical and non-medical
applications. The core strength of SINTX Technologies is the
manufacturing, research, and development of silicon nitride
ceramics for external partners. The Company presently manufactures
silicon nitride powders and components in its FDA registered and
ISO 13485:2016 certified manufacturing facility.
For more information on SINTX Technologies or its silicon
nitride material platform, please visit www.sintx.com.
About ImQuest BioSciences Inc.
ImQuest BioSciences, Inc. (http://imquestbio.com/), based in
Frederick, Maryland, is a contract research organization (CRO)
focused on assisting their biotechnology and pharmaceutical company
clients in the development of agents for the prevention and
treatment of infectious disease, cancer and inflammation. ImQuest’s
proprietary ImQuestSUCCESS platform for virology, microbiology,
topical microbicides, and cancer has assisted their clients in
expediting the development of products for clinical evaluation
through rapid identification of candidates with a high probability
of clinical success by reducing the risk associated with failure
experienced during clinical development.
Forward-Looking Statements
SINTX Technologies: This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 (PSLRA) that are subject to a number of risks
and uncertainties. Risks and uncertainties that may cause such
differences include, among other things; the collaboration with
O2TODAY may not result in the development of any products; that
SINTX has not as yet developed any products with antiviral
properties which incorporate the use of silicon nitride; products
developed under the joint development agreement may not be
effective against the SARS-CoV-2 virus; incorporation of silicon
nitride into personal protective equipment may not be safe or
effective; volatility in the price of SINTX’s common stock; the
uncertainties inherent in new product development, including the
cost and time required to commercialize such product(s); market
acceptance of our products once commercialized; SINTX’s ability to
raise additional funding and other competitive developments.
Readers are cautioned not to place undue reliance on the
forward-looking statements, which speak only as of the date on
which they are made and reflect management’s current estimates,
projections, expectations and beliefs. There can be no assurance
that any of the anticipated results will occur on a timely basis or
at all due to certain risks and uncertainties, a discussion of
which can be found in SINTX’s Risk Factors disclosure in its Annual
Report on Form 10-K, filed with the Securities and Exchange
Commission (SEC) on March 26, 2020, and in SINTX’s other filings
with the SEC. SINTX disclaims any obligation to update any
forward-looking statements. SINTX undertakes no obligation to
publicly revise or update the forward-looking statements to reflect
events or circumstances that arise after the date of this
report.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200902005308/en/
Business Inquiries for SINTX: SINTX Technologies
801.839.3502 IR@sintx.com
Media Inquiries for SINTX: Amanda Barry Associate
Director, Content and PR The Summit Group +1 509.554.8409
abarry@summitslc.com
SiNtx Technologies (NASDAQ:SINT)
Historical Stock Chart
From Feb 2024 to Mar 2024
SiNtx Technologies (NASDAQ:SINT)
Historical Stock Chart
From Mar 2023 to Mar 2024